Digital Content 
NEWS #PharmaBuzz
26 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/27/3282095/0/en/crinetics-pharmaceuticals-announces-the-european-commission-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults.html
26 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/26/3263394/0/en/Crinetics-Pharmaceuticals-Announces-Submission-of-Marketing-Authorization-Application-in-Brazil-for-Palsonify-Paltusotine-in-Acromegaly.html
03 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/03/3198798/0/en/Crinetics-Announces-First-Patient-Dosed-in-Phase-1-2-Trial-Evaluating-CRN09682-for-the-Treatment-of-Neuroendocrine-Tumors-and-Other-Somatostatin-Receptor-2-Expressing-Tumors.html
12 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-supplies-the-first-patient-dose-of-225ac-sso110-for-ariceum-therapeutics-phase-12-santana-225-clinical-trial-in-extensive-stage-small-cell-lung-cancer-and-merkel-cell-carcinoma-302612102.html
25 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/25/3174139/0/en/ITM-Announces-Analyses-from-Phase-3-COMPETE-Data-Showing-Higher-Objective-Response-Rates-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-Across-Subgroups-of-Patients-with-GEP-NET.html
04 Jan 2022
// TRIALSITENEWS
https://trialsitenews.com/results-from-amyrt-pharmas-phase-3-mpowered-trial-of-mycapssa-oral-octreotide-for-acromegaly-published-in-the-lancet-diabetes-endocrinology/
Share